Spotlight on nuclear PD-L1 in ovarian cancer chemoresistance: hidden but mighty
These findings indicate that nuclear PD-L1 serves as a poor prognostic marker in OVCA, being associated with tumor recurrence, chemoresistance, and reduced overall survival. Targeting nuclear PD-L1 may represent a novel therapeutic strategy to improve outcomes in patients with OVCA.
Authors
- Arvind Singh Mer (ORCID: https://orcid.org/0000-0001-8510-7963)
- Benjamin K. Tsang (ORCID: https://orcid.org/0000-0003-1213-3946)
- Laudine Communal (ORCID: https://orcid.org/0000-0002-0651-944X)
- Anne‐Marie Mes‐Masson (ORCID: https://orcid.org/0000-0002-6498-266X)
- Shivanshi Tripathi
- Meshach Asare-Werehene
- Arvin Zaker (ORCID: https://orcid.org/0009-0000-8922-9132)
- Eurı́dice Carmona
Institutions
- University of Ottawa (CA)
- Université du Québec à Montréal (CA)
- Ottawa Hospital (CA)
- Institute for Research in Immunology and Cancer (CA)
- Centre Hospitalier de l’Université de Montréal (CA)
- Institute of Infection and Immunity (CA)
- Ottawa University (US)
Publication Details
- Journal
- Frontiers in Immunology
- Published
- 2025-07-14
- DOI
- https://doi.org/10.3389/fimmu.2025.1543529
- Primary Topic
- Galectins and Cancer Biology
- Type
- article
- Field-Weighted Citation Impact
- 0.00